Kinase Inhibitor Drugs
John Wiley & Sons Inc (Verlag)
978-0-470-27829-1 (ISBN)
- Lieferbar
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
A comprehensive resource on case studies of marketed kinase drugs and promising drug trials
Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes:
Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery
Current thinking on kinase structure, biochemistry, and signal transduction pathways
Information on state-of-the-art technologies and tools such as structure-based and fragment-based drug discovery
A lineup of clinical-phase growth factor receptor inhibitors
Inhibitors of cell cycle kinases
The discovery of allosteric inhibitors of MEK kinase
Information on pharmacogenomics and its application to kinase inhibitor clinical development
Rongshi Li, PhD, is an Associate Professor in the Drug Discovery Department at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Jeffrey A. Stafford, PhD, has led drug discovery research at GlaxoSmithKline, Syrrx, and Takeda. He is a co-inventor of the tyrosine kinase inhibitor, pazopanib (Armala).
Preface ix
Contributors xiii
Part I Growth Factor Inhibitors: Vegfr2, Erbb2, And other Kinases 1
1 Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis 3
Connie L. Sun, James G. Christensen, and Gerald McMahon
2 Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor 41
Karen Lackey and G. Stuart Cockerill Copyrighted Material
3 Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor 57
Philip A. Harris and Jeffrey A. Stafford
4 Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor 79
Michael Michaelides and Daniel H. Albert
5 Discovery of Motesanib 113
Andrew S. Tasker and Vinod F. Patel
6 Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor 131
Rajeev S. Bhide and Joseph Fargnoli
7 Structure-Based Design and Characterization of Axitinib 167
Robert S. Kania
Part II Growth Factor Inhibitors: Mek Inhibitors 203
8 Road to PD0325901 and Beyond: The MEK Inhibitor Quest 205
Judith S. Sebolt-Leopold and Alexander J. Bridges
9 Discovery of Allosteric MEK Inhibitors 229
Eli Wallace and James F. Blake
Part III Cell Cycle Kinase Inhibitors: Aurora Kinase and Plk Inhibitors 253
10 Discovery of MK-0457 (VX-680) 255
Julian M. C. Golec
11 Discovery of PHA-739358 281
Daniele Fancelli and Jürgen Moll
12 Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity 309
Kevin M. Foote and Andrew A. Mortlock
13 Case Study of Aurora-A Inhibitor MLN8054 333
Christopher F. Claiborne and Mark G. Manfredi
14 Discovery of GSK461364: A Polo-like Kinase 1 Inhibitor for the Treatment of Cancer 351
Kevin W. Kuntz and Kyle A. Emmitte
Part IV Related Special Topics 365
15 Pharmacogenomics of Dasatinib (Sprycel TM) 367
Fei Huang and Edwin A. Clark
16 Practical Use of Computational Chemistry in Kinase Drug Discovery 403
James M. Veal
17 Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome 433
Victoria A. Feher and J. David Lawson
18 Fragment-Based Drug Discovery of Kinase Inhibitors 461
Daniel A. Erlanson
19 Protein Kinase Structural Biology: Methods and Strategies for Targeted Drug Discovery 485
Clifford D. Mol, Kengo Okada, and David J. Hosfield
Index 501
| Reihe/Serie | Wiley series in drug discovery and development |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 165 x 244 mm |
| Gewicht | 875 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Naturwissenschaften ► Chemie | |
| ISBN-10 | 0-470-27829-3 / 0470278293 |
| ISBN-13 | 978-0-470-27829-1 / 9780470278291 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
